|
|
|
|
| LEADER |
03211nam a2200277 u 4500 |
| 001 |
EB001839613 |
| 003 |
EBX01000000000000001003602 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
180702 r ||| eng |
| 100 |
1 |
|
|a Gartlehner, Gerald
|
| 245 |
0 |
0 |
|a Comparison of effects as evidence evolves from single trials to high-quality bodies of evidence
|h Elektronische Ressource
|c investigators, Gerald Gartlehner, Andreea Dobrescu, Tammeka Swinson Evans, Kylie Thaler, Barbara Nussbaumer, Isolde Sommer, Kathleen N. Lohr
|
| 260 |
|
|
|a Rockville (MD)
|b Agency for Healthcare Research and Quality (US)
|c March 2015, 2015
|
| 300 |
|
|
|a 1 PDF file (vi, 25 pages)
|b illustrations
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Comparative Effectiveness Research
|
| 653 |
|
|
|a Clinical Trials as Topic
|
| 710 |
2 |
|
|a United States
|b Agency for Healthcare Research and Quality
|
| 710 |
2 |
|
|a RTI International-University of North Carolina Evidence-based Practice Center
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a Research white paper
|
| 500 |
|
|
|a Title from PDF title page
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK286188
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a OBJECTIVE: The objective of our methods project was to use a diverse sample of medical interventions to assess empirically whether first trials rendered substantially different treatment effect estimates than reliable, high-quality bodies of evidence. STUDY DESIGN AND SETTING: We employed a meta-epidemiological study design using 100 bodies of evidence from Cochrane reports that had been graded as high quality of evidence. To determine the concordance of effect estimates between first and subsequent trials, we applied both quantitative and qualitative approaches. For quantitative assessment, we used Lin's concordance correlation and calculated z-scores; to determine the magnitude of differences of treatment effects, we calculated standardized mean differences (SMDs) and ratios of relative risks. We determined qualitative concordance based on a 2-tiered approach incorporating changes in statistical significance and magnitude of effect. RESULTS: First trials both over- and under-estimated the true treatment effects in no discernible pattern. Nevertheless, depending on the definition of concordance, effect estimates of first trials were concordant with pooled subsequent studies in at least 33 percent but up to 50 percent of comparisons. The pooled magnitude of change as bodies of evidence advanced from single trials to high-quality bodies of evidence was 0.16 SMD (95% confidence interval [CI], 0.12 to 0.21). In 80 percent of comparisons the difference in effect estimates was smaller than 0.5 SMDs. In first trials with large treatment effects (>0.5 SMD), however, estimates of effect substantially changed as new evidence accrued (mean change 0.68 SMD, 95% CI, .50 to 0.86) CONCLUSION: Results of first trials often change but the magnitude of change, on average, is small. Exceptions are first trials that present large treatment effects which often dissipate as new evidence accrues
|